Peptide · Fact sheet
Ipamorelin
Also known as ipamorelin acetate
Ipamorelin is an experimental peptide that can stimulate growth-hormone release. It is not an FDA-approved medicine, and FDA has described important evidence gaps and potential safety concerns.
What is Ipamorelin?
Ipamorelin is a synthetic growth hormone secretagogue that acts at the ghrelin receptor.
It has been investigated in human research, including studies of gastrointestinal motility, but that does not establish common online claims.
Benefits people look for
It is promoted for muscle, recovery, sleep, fat loss, and anti-aging, often in combination with CJC-1295.
Combination marketing makes it harder to know which ingredient caused an effect or adverse event.
What the evidence supports
- Studies confirm pharmacologic effects on hormone signaling.
- Evidence does not yet establish a favorable benefit-risk profile for popular consumer uses.
All research areas
- Growth hormone release
- Gastrointestinal motility
- Postoperative ileus
- Growth-hormone and gastrointestinal pathway effects
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
Easier sleep with daytime sleepiness and vivid dreams
A person using products labeled ipamorelin and CJC-1295 without DAC reported falling asleep easily, vivid dreams, lower motivation and unwanted daytime sleepiness.
Combined exposure prevents attribution to ipamorelin. The accompanying product was labeled CJC-1295 without DAC, not the long-acting CJC-1295 studied in the cited clinical research.
Read the sleepiness report ↗Side effects & risks
- FDA describes potential immune reactions and complexities related to impurities and peptide characterization.
- FDA notes serious adverse events, including deaths, in a study using intravenous ipamorelin for gastric motility; that context does not establish cause for every event but is a serious signal.
- Safety information for other routes and long-term use is insufficient.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceHuman studies exist, but they do not provide strong evidence for the broad performance, recovery, or anti-aging outcomes promoted to consumers.
Selected research to read
Registry record for an ipamorelin postoperative ileus study.
Human pharmacology study characterizing ipamorelin exposure and growth-hormone responses.
Randomized proof-of-concept study of ipamorelin for postoperative ileus.
FDA approval & research status
Ipamorelin is not FDA approved. FDA has described potential immunogenicity and impurity concerns and insufficient safety information for certain routes.
No FDA-approved use is documented in the records summarized on this page.
Mid-stage study completed without approval
Ipamorelin reached a Phase 2 postoperative-ileus study, but it has no FDA-approved product and the cited research does not support broad consumer wellness claims.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Long-term safety and uncommon adverse effects
- Meaningful benefits for body composition, recovery, sleep, or aging
- Safety of combinations promoted online
- Product identity, purity, and consistency outside approved manufacturing
The takeaway
Ipamorelin affects a real biological pathway, but it is unapproved and lacks strong evidence for the outcomes commonly used to market it.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2clinical trialsClinicalTrials.gov: ipamorelin for postoperative ileus
Registry record for an ipamorelin postoperative ileus study.
- 3pubmedIpamorelin pharmacokinetic-pharmacodynamic study
Human pharmacology study characterizing ipamorelin exposure and growth-hormone responses.
- 4pubmedIpamorelin postoperative ileus proof-of-concept study
Randomized proof-of-concept study of ipamorelin for postoperative ileus.